GLOW names a proposed combination of GHK-Cu, BPC-157 and TB-500. It does not, by itself, define a reproducible research material. The complete identity of each ingredient, the amount of each, and the finished formulation must be established before a component paper can be connected to a blend experiment. The most consequential ambiguity is TB-500: a seven-residue fragment and full-length thymosin beta-4 are different test articles.
Three names with different identity questions
GHK is glycyl-L-histidyl-L-lysine, a tripeptide that binds copper. GHK-Cu describes a copper complex, not simply the peptide without its metal. Early fibroblast research specifically investigated that complex. A specification should therefore distinguish peptide content, copper content and the intended complex rather than treating all three as the same measurement. Primary GHK-Cu study
BPC-157 is a 15-residue peptide. FDA's July 2026 presentation distinguishes its free-base and acetate forms; naming the active peptide does not identify the salt supplied. A paper's BPC-157 label also cannot authenticate the form, purity or amount in a different lot. These distinctions matter when investigators compare preparations, because an apparent biological difference could begin with a material difference. FDA BPC-157 presentation
FDA's detailed TB-500 briefing uses the name for the N-acetylated seven-residue peptide Ac-LKKTETQ-OH. Full-length thymosin beta-4 has 43 residues, while the non-acetylated seven-residue LKKTETQ is another distinct material. Terminal chemistry is part of identity, not an optional annotation. FDA TB-500 identity assessment
Amount and ratio need a defined basis
The Serum Research catalog inventory reviewed for this article has a GLOW URL containing component amounts, while the audited blend guide records incomplete visible composition documentation. A URL is not a batch assay. The label, specification and laboratory report must agree before those numbers can serve as experimental inputs. The existing peptide-blend evidence guide documents that unresolved catalog boundary.
Total powder weight does not determine how much of each intended peptide is present. Nor does a mass ratio necessarily equal a ratio of molecules: molecular identities and their masses are needed for that conversion. Copper, counterions, residual water and formulation ingredients also require an explicit accounting convention. These are analytical questions, not instructions for preparing or using a blend.
Connecting identity to an experiment
A useful evidence record connects a named sample to its lot, component identities, individual contents and method results. The experiment then records the same test article, not merely another vial bearing the word GLOW. An analytical study that separated copper-containing liposomal preparations illustrates why a signal must be assigned to the material actually measured; it did not validate GLOW. Copper-complex analytical study
Resolving composition would make research interpretable, but would not establish clinical benefit. Identity answers what was tested. A controlled experiment answers what happened under its conditions. Human efficacy and safety require further evidence and cannot be supplied by a composition certificate.
The separate GHK-Cu and TB-500 identity records provide component background without treating those records as blend validation.
This research appraisal was prepared for Serum Research, a commercial supplier. It does not independently validate its catalog products or provide medical or administration advice.
Published by Serum Research. Sources checked 2026-10-06. How we review evidence · Send a correction.